We believe the planned acquisition of DSS Group makes strategic sense.
In the quarter, the specialty pharmaceutical name had sequential sales growth for three of its four drugs.
We maintain our One rating on the stock, which is trading 4% higher today.
We believe the stock is oversold at current levels and that it will bounce back after the company's accounting issue is resolved.
Depomed, McDermott and SandRidge Energy are all scheduled to release their numbers after the close.
In the recent decline in energy prices, the pain has been especially concentrated in energy stocks trading under $10. Here are four highly levered names to watch.
Amid a furious rally this week, we used post-earnings declines in two names to add to model portfolio positions.
Orders slowed toward the end of the quarter, but the trend is already reversing.
We would consider adding to our position in a pullback.
The numbers came in below views -- but we continue to believe the company is leveraged to a low-interest-rate environment.